273 related articles for article (PubMed ID: 26369543)
1. Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.
Chen S; Zhu X; Qiao H; Ye M; Lai X; Yu S; Ding L; Wen A; Zhang J
Tumour Biol; 2016 Feb; 37(2):2321-31. PubMed ID: 26369543
[TBL] [Abstract][Full Text] [Related]
2. Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells.
Chen S; Li X; Feng J; Chang Y; Wang Z; Wen A
Med Hypotheses; 2011 Aug; 77(2):206-8. PubMed ID: 21570197
[TBL] [Abstract][Full Text] [Related]
3. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
4. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
5. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
6. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
Zhu X; Wu L; Qiao H; Han T; Chen S; Liu X; Jiang R; Wei Y; Feng D; Zhang Y; Ma Y; Zhang S; Zhang J
J Cell Biochem; 2013 Dec; 114(12):2643-53. PubMed ID: 23794518
[TBL] [Abstract][Full Text] [Related]
7. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
8. Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS.
Zhang R; Qiao H; Chen S; Chen X; Dou K; Wei L; Zhang J
Cancer Biol Ther; 2016 Sep; 17(9):925-34. PubMed ID: 27416292
[TBL] [Abstract][Full Text] [Related]
9. Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation.
Mele L; la Noce M; Paino F; Regad T; Wagner S; Liccardo D; Papaccio G; Lombardi A; Caraglia M; Tirino V; Desiderio V; Papaccio F
J Exp Clin Cancer Res; 2019 Apr; 38(1):160. PubMed ID: 30987650
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells.
Ma C; Zuo W; Wang X; Wei L; Guo Q; Song X
Oncol Rep; 2013 Feb; 29(2):812-8. PubMed ID: 23229346
[TBL] [Abstract][Full Text] [Related]
11. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
Zhang D; Pal A; Bornmann WG; Yamasaki F; Esteva FJ; Hortobagyi GN; Bartholomeusz C; Ueno NT
Mol Cancer Ther; 2008 Jul; 7(7):1846-50. PubMed ID: 18644997
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
13. Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.
Zhao H; Faltermeier CM; Mendelsohn L; Porter PL; Clurman BE; Roberts JM
Oncotarget; 2014 Dec; 5(24):12704-14. PubMed ID: 25587029
[TBL] [Abstract][Full Text] [Related]
14. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.
Yeh ES; Abt MA; Hill EG
Breast Cancer Res Treat; 2015 Jan; 149(1):91-8. PubMed ID: 25515931
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells.
Huang WC; Hung CM; Wei CT; Chen TM; Chien PH; Pan HL; Lin YM; Chen YJ
Oncotarget; 2016 Sep; 7(38):62352-62363. PubMed ID: 27694691
[TBL] [Abstract][Full Text] [Related]
16. HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.
Tracey N; Creedon H; Kemp AJ; Culley J; Muir M; Klinowska T; Brunton VG
Breast Cancer Res Treat; 2020 Feb; 179(3):543-555. PubMed ID: 31705351
[TBL] [Abstract][Full Text] [Related]
17. RON confers lapatinib resistance in HER2-positive breast cancer cells.
Wang Q; Quan H; Zhao J; Xie C; Wang L; Lou L
Cancer Lett; 2013 Oct; 340(1):43-50. PubMed ID: 23811285
[TBL] [Abstract][Full Text] [Related]
18. Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.
Zhang L; Ngo JA; Wetzel MD; Marchetti D
Neoplasia; 2015 Jan; 17(1):101-13. PubMed ID: 25622903
[TBL] [Abstract][Full Text] [Related]
19. Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.
Bai M; Song N; Che X; Wang X; Qu X; Liu Y
Cell Biol Int; 2018 Jul; 42(7):781-793. PubMed ID: 29271513
[TBL] [Abstract][Full Text] [Related]
20. t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib.
Christenson JL; Denny EC; Kane SE
Oncotarget; 2015 Oct; 6(32):33134-45. PubMed ID: 26430732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
